Expanding gene therapy for Usher Syndrome Type 2A – Ophthalmology Times


Modern RetinaModern Retina
Ophthalmology Times EuropeOphthalmology Times Europe
Ophthalmology TimesOphthalmology Times

SPOTLIGHT
A University of Houston researcher has been awarded a $1.6 million grant to help restore vision loss in patients with the rare disease that causes blindness.
A University of Houston researcher is expanding a method of gene therapy
Muna Naash, PhD, University of Houston John S. Dunn Endowed Professor of biomedical engineering, is expanding a method of gene therapy with the hopes it will restore vision loss in Usher Syndrome Type 2A. (Image courtesy of University of Houston)
with the hopes it will restore vision loss in Usher Syndrome Type 2A (USH2A), a rare genetic disease. The National Eye Institute has awarded Muna Naash, PhD, John S. Dunn Endowed Professor of biomedical engineering, $1.6 million to support her work.
According to a University of Houston news release, Usher Syndrome Type 2A, caused by mutations of the USH2A gene, can include hearing loss from birth and progressive loss of vision, prompting retinitis pigmentosa (RP). RP affects the retina, the eye’s light-sensitive layer, leading to a breakdown of cells in the retina which causes blindness. Currently no treatment exists for USH2A.
“Our goal is to advance our current intravitreal gene therapy platform consisting of DNA nanoparticles/hyaluronic acid nanospheres to deliver large genes in order to develop safe and effective therapies for visual loss in Usher Syndrome Type 2A,” Naash said in the news release.
Gene therapy is the introduction of a normal gene into cells to correct genetic disorders. Intravitreal treatment consists of injections directly into the vitreal chamber of the eye.
“Developing an effective treatment for USH2A has been challenging due to its large coding sequence (15.8 kb) that has precluded its delivery using standard approaches and the presence of multiple isoforms with functions that are not fully understood,” said Naash, who will also evaluate the long-term efficacy of the best therapeutic platform for future translation to the clinic, according to the news release.
To rescue vision loss, Naash’s non-viral therapy targets the mutation in usherin, the protein product that causes Usher Syndrome Type 2A. Naash has already cloned two usherin isoforms to be tested with her innovative platform to safely advance gene therapy for USH2A.
“Understanding which isoforms of usherin are expressed in the retina and the cochlea and what role they play (in contrast to mutant pathogenic forms) is essential in developing an effective gene therapy construct,” Naash said in the release.
The work will provide a solid foundation for understanding the function of each usherin isoform and developing an effective gene therapy platform to treat USH2A associated visual defects, she said in the news release.
Glaucoma 360: Innovation taking center stage
Commercial real estate and your practice, part two with Colin Carr
Harrow closes acquisition of U.S. rights to Novartis drugs
Tips, tricks, what to dos and what not to dos on how you can save money as a healthcare provider on your commercial real estate (Part 1)
ARVO announces the winners of multiple awards
EnVision Summit 2023: Unique program takes family friendly conference to new heights
2 Clarke Drive
Cranbury, NJ 08512
609-716-7777

source


Leave a Reply

Your email address will not be published.